WO2003105776A3 - ANALOGUES OF LIPID MEDIATORS DERIVED FROM OMEGA-3 PUFAs AND METHODS OF USE - Google Patents
ANALOGUES OF LIPID MEDIATORS DERIVED FROM OMEGA-3 PUFAs AND METHODS OF USE Download PDFInfo
- Publication number
- WO2003105776A3 WO2003105776A3 PCT/US2003/019019 US0319019W WO03105776A3 WO 2003105776 A3 WO2003105776 A3 WO 2003105776A3 US 0319019 W US0319019 W US 0319019W WO 03105776 A3 WO03105776 A3 WO 03105776A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- analogues
- lipid mediators
- pufas
- omega
- methods
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/40—Unsaturated compounds
- C07C59/58—Unsaturated compounds containing ether groups, groups, groups, or groups
- C07C59/64—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings
- C07C59/66—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings the non-carboxylic part of the ether containing six-membered aromatic rings
- C07C59/68—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings the non-carboxylic part of the ether containing six-membered aromatic rings the oxygen atom of the ether group being bound to a non-condensed six-membered aromatic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
- C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C235/28—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and unsaturated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
- C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C235/32—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
- C07C235/34—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/40—Unsaturated compounds
- C07C59/42—Unsaturated compounds containing hydroxy or O-metal groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/40—Unsaturated compounds
- C07C59/42—Unsaturated compounds containing hydroxy or O-metal groups
- C07C59/48—Unsaturated compounds containing hydroxy or O-metal groups containing six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/40—Unsaturated compounds
- C07C59/58—Unsaturated compounds containing ether groups, groups, groups, or groups
- C07C59/64—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
- C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
- C07C69/73—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids
- C07C69/732—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids of unsaturated hydroxy carboxylic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
- C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
- C07C69/73—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids
- C07C69/734—Ethers
- C07C69/736—Ethers the hydroxy group of the ester being etherified with a hydroxy compound having the hydroxy group bound to a carbon atom of a six-membered aromatic ring
Abstract
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE60318456T DE60318456T2 (en) | 2002-06-17 | 2003-06-13 | ANALOGUE OF OMEGA-3 PUFA DERIVED LIPID MEDIATORS AND METHOD OF USE |
EP03737135A EP1537069B1 (en) | 2002-06-17 | 2003-06-13 | ANALOGUES OF LIPID MEDIATORS DERIVED FROM OMEGA-3 PUFAs AND METHODS OF USE |
JP2004512684A JP2005529945A (en) | 2002-06-17 | 2003-06-13 | Omega-3 PUFA derived lipid mediator analogs and methods of use |
AU2003238240A AU2003238240A1 (en) | 2002-06-17 | 2003-06-13 | ANALOGUES OF LIPID MEDIATORS DERIVED FROM OMEGA-3 PUFAs AND METHODS OF USE |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US38962202P | 2002-06-17 | 2002-06-17 | |
US60/389,622 | 2002-06-17 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2003105776A2 WO2003105776A2 (en) | 2003-12-24 |
WO2003105776A3 true WO2003105776A3 (en) | 2004-09-16 |
Family
ID=29736662
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2003/019019 WO2003105776A2 (en) | 2002-06-17 | 2003-06-13 | ANALOGUES OF LIPID MEDIATORS DERIVED FROM OMEGA-3 PUFAs AND METHODS OF USE |
Country Status (7)
Country | Link |
---|---|
US (2) | US7378444B2 (en) |
EP (1) | EP1537069B1 (en) |
JP (1) | JP2005529945A (en) |
AT (1) | ATE382597T1 (en) |
AU (1) | AU2003238240A1 (en) |
DE (1) | DE60318456T2 (en) |
WO (1) | WO2003105776A2 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9364454B2 (en) | 2005-10-03 | 2016-06-14 | The Brigham And Women's Hospital, Inc. | Anti-inflammatory actions of neuroprotectin D1/protectin D1 and its natural stereoisomers |
Families Citing this family (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1296923B3 (en) | 2000-02-16 | 2012-04-11 | The Brigham And Women's Hospital, Inc. | Aspirin-triggered lipid mediators |
US7030159B2 (en) * | 2001-12-18 | 2006-04-18 | The Brigham And Women's Hospital, Inc. | Approach to anti-microbial host defense with molecular shields with EPA and DHA analogs |
US8481772B2 (en) | 2002-04-01 | 2013-07-09 | University Of Southern California | Trihydroxy polyunsaturated eicosanoid derivatives |
US7582785B2 (en) * | 2002-04-01 | 2009-09-01 | University Of Southern California | Trihydroxy polyunsaturated eicosanoid derivatives |
EP2022775B1 (en) * | 2002-04-01 | 2014-10-15 | University of Southern California | Trihydroxy polyunsaturated eicosanoids |
US7902257B2 (en) | 2002-04-01 | 2011-03-08 | University Of Southern California | Trihydroxy polyunsaturated eicosanoid |
US7759395B2 (en) | 2002-08-12 | 2010-07-20 | The Brigham And Women's Hospital, Inc. | Use of docosatrienes, resolvins and their stable analogs in the treatment of airway diseases and asthma |
EP2216318B1 (en) | 2002-08-12 | 2018-10-10 | Brigham And Women's Hospital | Resolvins: Biotemplates for therapeutic interventions |
WO2004078143A2 (en) * | 2003-03-05 | 2004-09-16 | The Brigham And Women's Hospital Inc. | Methods for identification and uses of anti-inflammatory receptors for eicosapentaenoic acid analogs |
US20050238589A1 (en) * | 2004-04-14 | 2005-10-27 | Van Dyke Thomas E | Methods and compositions for preventing or treating periodontal diseases |
US20070265341A1 (en) * | 2004-07-01 | 2007-11-15 | The Schepens Eye Research Institute Inc. | Compositions and methods for treating eye disorders and conditions |
CA2572344A1 (en) * | 2004-07-01 | 2006-01-19 | Schepens Eye Research | Compositions and methods for treating eye disorders and conditions |
US20060293288A1 (en) * | 2005-01-07 | 2006-12-28 | Serhan Charles N | Use of resolvins to treat gastrointestinal diseases |
WO2007061783A1 (en) * | 2005-11-18 | 2007-05-31 | Trustees Of Boston University | Treatment and prevention of bone loss using resolvins |
CN101528218A (en) * | 2006-07-19 | 2009-09-09 | 雷索维克斯药品公司 | Compositions and methods for the treatment of mucositis |
WO2008063772A2 (en) * | 2006-10-13 | 2008-05-29 | The Brigham And Women's Hospital Inc. | Resolvin d series and protectin d1 mitigate acute kidney injury |
WO2008057283A2 (en) * | 2006-10-26 | 2008-05-15 | Resolvyx Pharmaceuticals, Inc. | Use of resolvins for inhibition of bone loss |
WO2008070129A2 (en) * | 2006-12-05 | 2008-06-12 | Resolvyx Pharmaceuticals, Inc. | Compositions and methods for the treatment of inflammatory disease |
WO2009038671A2 (en) * | 2007-09-14 | 2009-03-26 | Resolvyx Pharmaceuticals, Inc. | Oxylipin compounds for treating autoimmune diseases |
AU2014201375B2 (en) * | 2007-10-12 | 2015-11-05 | Resolvyx Pharmaceuticals, Inc. | Omega-3 fatty acids, hydroxy polyunsaturated fatty acids, lipoxin compounds, or oxylipin compounds for the treatment of ophthalmic conditions |
AU2008312006B2 (en) * | 2007-10-12 | 2013-12-12 | Resolvyx Pharmaceuticals, Inc. | Omega-3 fatty acids, hydroxy polyunsaturated fatty acids, lipoxin compounds, or oxyliptin compounds for the treatment of ophthalmic conditions |
WO2009154873A2 (en) * | 2008-04-25 | 2009-12-23 | The Brigham And Women's Hospital, Inc. | Use of novel lipid mediators to inhibit angiogenesis |
EP2344441B1 (en) | 2008-09-16 | 2016-02-17 | The Brigham And Women's Hospital Inc. | 7,14-dihydroxy-docosahexaenoic acid compounds |
EP2393353A4 (en) * | 2009-02-05 | 2013-12-25 | Resolvyx Pharmaceuticals Inc | Compositions and methods for organ preservation |
WO2011011882A1 (en) * | 2009-07-29 | 2011-02-03 | Phenomenome Discoveries Inc. | Hydroxy fatty acid compounds and uses thereof for disease treatment and diagnosis |
US8952000B2 (en) | 2011-02-16 | 2015-02-10 | Pivotal Therapeutics Inc. | Cholesterol absorption inhibitor and omega 3 fatty acids for the reduction of cholesterol and for the prevention or reduction of cardiovascular, cardiac and vascular events |
US8715648B2 (en) | 2011-02-16 | 2014-05-06 | Pivotal Therapeutics Inc. | Method for treating obesity with anti-obesity formulations and omega 3 fatty acids for the reduction of body weight in cardiovascular disease patients (CVD) and diabetics |
US9119826B2 (en) | 2011-02-16 | 2015-09-01 | Pivotal Therapeutics, Inc. | Omega 3 fatty acid for use as a prescription medical food and omega 3 fatty acid diagniostic assay for the dietary management of cardiovascular patients with cardiovascular disease (CVD) who are deficient in blood EPA and DHA levels |
US8951514B2 (en) | 2011-02-16 | 2015-02-10 | Pivotal Therapeutics Inc. | Statin and omega 3 fatty acids for reduction of apolipoprotein-B levels |
US10383839B2 (en) | 2011-06-30 | 2019-08-20 | Johnson & Johnson Vision Care, Inc. | Esters for treatment of ocular inflammatory conditions |
JP5971424B2 (en) * | 2013-08-27 | 2016-08-17 | 日産自動車株式会社 | Double link piston crank mechanism for internal combustion engine |
WO2017077528A2 (en) * | 2015-11-02 | 2017-05-11 | Salzman Lovelace Investments, Ltd. | Methods and pharmaceutical compositions for treatment of lung inflammation |
US10006925B2 (en) | 2016-05-30 | 2018-06-26 | Universal Diagnostics, S. L. | Methods and systems for metabolite and/or lipid-based detection of colorectal cancer and/or adenomatous polyps |
CA3026264A1 (en) | 2016-06-03 | 2017-12-07 | Thetis Pharmaceuticals Llc | Compositions and methods relating to salts of specialized pro-resolving mediators |
GB201611920D0 (en) * | 2016-07-08 | 2016-08-24 | Astrazeneca Ab | Pharmaceutical compositions |
WO2020076578A1 (en) | 2018-10-09 | 2020-04-16 | University Of Rochester | Treatment of vulvovaginal disorders |
WO2023168245A2 (en) | 2022-03-03 | 2023-09-07 | Thetis Pharmaceuticals Llc | Cyclodextrin complexes of specialized proresolving mediators |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001060778A2 (en) * | 2000-02-16 | 2001-08-23 | The Brigham And Women's Hospital, Inc. | Aspirin-triggered lipid mediators |
WO2003053423A2 (en) * | 2001-12-18 | 2003-07-03 | The Brigham And Women's Hospital | Inhibition or prevention of infection by bacteria with epa, dha or analogs |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5411951A (en) | 1984-10-04 | 1995-05-02 | Monsanto Company | Prolonged release of biologically active somatotropin |
US5441951A (en) * | 1994-06-15 | 1995-08-15 | Brigham & Women's Hospital | Lipoxin compounds |
CA2365204C (en) | 1999-03-18 | 2009-10-27 | Brigham And Women's Hospital | Lipoxin compounds and their use |
EP1268393A2 (en) | 2000-03-20 | 2003-01-02 | Trustees Of Boston University | Lipoxin analogs and methods for the treatment of periodontal disease |
EP2022775B1 (en) | 2002-04-01 | 2014-10-15 | University of Southern California | Trihydroxy polyunsaturated eicosanoids |
-
2003
- 2003-06-13 AU AU2003238240A patent/AU2003238240A1/en not_active Abandoned
- 2003-06-13 AT AT03737135T patent/ATE382597T1/en not_active IP Right Cessation
- 2003-06-13 EP EP03737135A patent/EP1537069B1/en not_active Expired - Lifetime
- 2003-06-13 WO PCT/US2003/019019 patent/WO2003105776A2/en active IP Right Grant
- 2003-06-13 DE DE60318456T patent/DE60318456T2/en not_active Expired - Lifetime
- 2003-06-13 JP JP2004512684A patent/JP2005529945A/en active Pending
- 2003-06-13 US US10/460,913 patent/US7378444B2/en active Active
-
2008
- 2008-04-30 US US12/150,794 patent/US7595341B2/en not_active Expired - Lifetime
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001060778A2 (en) * | 2000-02-16 | 2001-08-23 | The Brigham And Women's Hospital, Inc. | Aspirin-triggered lipid mediators |
US20020055538A1 (en) * | 2000-02-16 | 2002-05-09 | Serhan Charles N. | Aspirin-triggered lipid mediators |
WO2003053423A2 (en) * | 2001-12-18 | 2003-07-03 | The Brigham And Women's Hospital | Inhibition or prevention of infection by bacteria with epa, dha or analogs |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9364454B2 (en) | 2005-10-03 | 2016-06-14 | The Brigham And Women's Hospital, Inc. | Anti-inflammatory actions of neuroprotectin D1/protectin D1 and its natural stereoisomers |
Also Published As
Publication number | Publication date |
---|---|
AU2003238240A8 (en) | 2003-12-31 |
DE60318456D1 (en) | 2008-02-14 |
US20080207753A1 (en) | 2008-08-28 |
DE60318456T2 (en) | 2008-12-24 |
AU2003238240A1 (en) | 2003-12-31 |
WO2003105776A2 (en) | 2003-12-24 |
ATE382597T1 (en) | 2008-01-15 |
US7378444B2 (en) | 2008-05-27 |
EP1537069A2 (en) | 2005-06-08 |
JP2005529945A (en) | 2005-10-06 |
US7595341B2 (en) | 2009-09-29 |
EP1537069A4 (en) | 2006-01-04 |
US20040044050A1 (en) | 2004-03-04 |
EP1537069B1 (en) | 2008-01-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2003105776A3 (en) | ANALOGUES OF LIPID MEDIATORS DERIVED FROM OMEGA-3 PUFAs AND METHODS OF USE | |
YU59303A (en) | Essential n-3 fatty acids in cardiac insufficiency and heart failure therapy | |
EP1698685A4 (en) | Fat composition | |
CY1105119T1 (en) | USE OF POLYUNSATURATED FATTY ACIDS FOR THE PRIMARY PREVENTION OF SERIOUS CARDIOVASCULAR EVENTS | |
DE60237358D1 (en) | ||
EP2510927A3 (en) | Use of dha, epa or dha-derived epa for treating a pathology associated with cellular oxidative damage | |
AR117404A2 (en) | DOSAGE UNIT INCLUDING A PROSTAGLANDIN ANALOGUE FOR THE TREATMENT OF CONSTIPATION | |
IL153458A0 (en) | Therapeutic combinations of fatty acids | |
DE60203494D1 (en) | USE OF COENZYME Q (UBIQUINONE) AND EICOSAPENTAIC ACID (EPA) FOR THE TREATMENT OF NON-HODGKIN'S LYMPHOMA AND PSYCHIATRIC OR NEUROLOGICAL DISEASES | |
WO2004078166A3 (en) | Use of omega-3-fatty acids in the treatment of diabetic patients | |
WO2002008401A3 (en) | Elongase genes and uses thereof | |
ATE416622T1 (en) | NON-HYDRATED HARD FAT | |
KR970707088A (en) | Modified polyunsaturated fatty acids (MODIFIED POLYUNSATURATED FATTY ACIDS) | |
EA200100895A1 (en) | IRRONABLE FATTY ACIDS FOR THE PREVENTION OF CARDIOVASCULAR ACCESSES | |
DK1121115T3 (en) | PUFA supplements | |
WO2002081668A8 (en) | Desaturase genes and uses thereof | |
EP3129455B1 (en) | Method for the production of a long chain monounsaturated fatty acid composition | |
BR0110664A (en) | Disposable edible fat composition, and, use of a combination of a citric acid ester of partial fatty acid glycerides and a salt | |
ATE306194T1 (en) | STABILIZED FAT MIXTURE, METHOD OF PRODUCING IT AND FOOD CONTAINING THE FAT | |
NO20014341L (en) | Dissolution of polyunsaturated fatty acids and derivatives thereof by formation of <gamma> cyclodextrin inclusion compositions and their use in pharmaceutical, cosmetic or food compositions | |
Raz et al. | Dietary fish oil inhibits Δ6‐desaturase activity in vivo | |
TW360545B (en) | Dermatologic preparation | |
JPH0477600A (en) | Method for obtaining lipid composition containing docosahexaenoic acid in high content | |
CN1212867A (en) | Composition for prevention and treatment of cardio-cerebralvascular disease | |
Black | Omega-3 fatty acids and non-melanoma skin cancer |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2004512684 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2003737135 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2003737135 Country of ref document: EP |
|
WWG | Wipo information: grant in national office |
Ref document number: 2003737135 Country of ref document: EP |